Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 6, 2009, Pages 600-606

  Hochberg, A M ^a   Hauben, M ^b,c,d,e  

^a ProSanos Corporation   (United States)

^b PFIZER INC   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; APOMORPHINE; ARIPIPRAZOLE; AZACITIDINE; BEHENYL ALCOHOL; CLOFARABINE; DARIFENACIN; ELETRIPTAN; ERLOTINIB; EZETIMIBE; ICODEXTRIN; LANTHANUM CARBONATE; MIFEPRISTONE; NITAZOXANIDE; OLMESARTAN; OXCARBAZEPINE; PEGAPTANIB; PREGABALIN; RIVASTIGMINE; ROSIGLITAZONE; SOLIFENACIN; TELITHROMYCIN; TINZAPARIN; TROSPIUM CHLORIDE; UNINDEXED DRUG; UNIPROST; UNOPROSTONE ISOPROPYL ESTER; VENLAFAXINE; VORICONAZOLE; ZONISAMIDE;

ARTICLE; DATA MINING; DATA MINING ALGORITHM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; TRADITIONAL SIGNALING CRITERIA; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATA INTERPRETATION, STATISTICAL; DECISION SUPPORT TECHNIQUES; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH DESIGN; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 67349261417     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.26     Document Type: Article

References (21)

1. Klein, D.F. & O'Brien, C.P. Improving detection of adverse efects of marketed drugs. JAMA 298, 333-334 (2007).
2. Alemenof, J.S., Pattishall, E.N., Gibbs, T.G., DuMouchel, W., Evans, S.J. & Yuen, N. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 82, 157-166 (2007).
3. Syed, R.A., Marks, N.S. & Goetsch, R.A. Spontaneous reporting in the United States. In Textbook of Pharmacoepidemiology (eds. Strom, B.L. & Kimmel, S.E.)91-116 (Wiley & Sons, West Sussex, England, 2006).
4. Gould, A.L. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol. Drug Saf. 12, 559-574 (2003).
5. Meyboom, R.H., Lindquist, M., Egberts, A.C. & Edwards, I.R. Signal selection and follow-up in pharmacovigilance. Drug Saf. 25, 459-465 (2002).
6. Almenof, J. et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 28, 981-1007 (2005).
7. Aronson, J.K. & Hauben, M. Anecdotes as evidence: the use of defnitive anecdotal adverse drug reactions as gold standards in pharmacovigilance. BMJ 332, 1267-1269 (2006).
8. Hauben, M. & Aronson, J.K. Gold standards in pharmacovigilance: the use of defnitive anecdotal reports of adverse drug reactions as pure gold and high grade ore. Drug Saf. 30, 645-655 (2007).
9. Hauben, M. & Aronson, J.K. Defning "signal" and its subtypes in pharmacovigilance based on a systematic review of previous defnitions. Drug Saf. 32, 99-110 (2009).
10. DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System (with discussion). Am. Stat. 53, 177-190 (1999).
11. Hochberg, A.M., Reisinger, S.J., Pearson, R.K., O'Hara, D.J. & Hall, K. Using data mining to predict safety actions from FDA Adverse Event Reporting System Data. Drug Inf. J. 41, 633-644 (2007).
12. Ross, S.M. Introduction to Probability Models 1-11 (Academic Press, New York, 1972).
13. Evans, S.J., Waller, P.C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483-486 (2001).
14. Hochberg, A.M. et al. An evaluation of three signal detection algorithms using a highly inclusive reference event database. Drug Saf. (in press).
15. Szarfman, A., Machado, S.G. & O'Neill, R.T. Use of screening algorithms and computer systems to efciently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002).
16. Hauben, M. Trimethoprim-induced hyperkalaemia - lessons in data mining. Br. J. Clin. Pharmacol. 58, 338-339 (2004).
17. Chan, K.A. & Hauben, M. Signal detection in pharmacovigilance: empirical evaluation of data mining tools. Pharmacoepidemiol. Drug Saf. 14, 597-599 (2005).
18. Hammond, I.W., Rich, D.S. & Gibbs, T.G. Efect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin. Drug Saf. 6, 705-712 (2007).
19. Joint Formulary Committee. British National Formulary 52nd edn. (British Medical Association and Royal Pharmaceutical Society of Great Britain, London, 2006).
20. Hauben, M. & Reich, L. Drug-induced pancreatitis: lessons in data mining. Br. J. Clin. Pharmacol. 58, 560-562 (2004).
21. Szarfman, A. & Levine, J. Memorandum: NDA 21-144 KETEK (Telithromycin) 400MG Tablets (Sanof-Aventis): Data Mining Analysis of Adverse Events and Outcomes Reported for Telithromycin and 15 Comparator Drugs (AERS Data). (2006). Accessed 16 June 2008.